相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of Antihyperglycemic Medications in US Adults: An Analysis of the National Health and Nutrition Examination Survey
Le Phuc et al.
DIABETES CARE (2020)
Cost-effectiveness of Diabetes Treatment Sequences to Inform Step Therapy Policies
Anna Hung et al.
AMERICAN JOURNAL OF MANAGED CARE (2020)
Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease Insights From Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)
Suzanne V. Arnold et al.
CIRCULATION (2019)
Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial
A. Kansal et al.
DIABETIC MEDICINE (2019)
Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial
Kohei Kaku et al.
CLINICAL THERAPEUTICS (2019)
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Mafalda Ramos et al.
DIABETES THERAPY (2019)
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017
Thomas R. Einarson et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
George Gourzoulidis et al.
CLINICAL DRUG INVESTIGATION (2018)
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
Michael J. B. van Baar et al.
DIABETES CARE (2018)
Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
Chakrapani Balijepalli et al.
DIABETES THERAPY (2018)
Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
Chakrapani Balijepalli et al.
DIABETES THERAPY (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Long-term Trends in Antidiabetes Drug Usage in the US: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes
Olga Montvida et al.
DIABETES CARE (2018)
Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics
J. Jaime Caro
PHARMACOECONOMICS (2016)
EQ-5D Scores for Diabetes-Related Comorbidities
Patrick W. Sullivan et al.
VALUE IN HEALTH (2016)
COST EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH T2DM AND HIGH CV RISK IN CANADA
S. R. Mettam et al.
VALUE IN HEALTH (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
Elizabeth S. Mearns et al.
PLOS ONE (2015)
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
Benjamin M. Leon et al.
WORLD JOURNAL OF DIABETES (2015)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
A. J. Hayes et al.
DIABETOLOGIA (2013)
Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study
Susan Grandy et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2012)
The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based Study
Albert Jan van Hoek et al.
PLOS ONE (2011)
EuroQol (EQ-5D) health utility scores for patients with migraine
Ruifeng Xu et al.
QUALITY OF LIFE RESEARCH (2011)
Economic models in type 2 diabetes
Y. Yi et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Peter Lindgren et al.
EUROPEAN HEART JOURNAL (2007)
Preference-based EQ-5D index scores for chronic conditions in the United States
Patrick W. Sullivan et al.
MEDICAL DECISION MAKING (2006)
A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
PM Clarke et al.
DIABETOLOGIA (2004)
分享论文
